Rose Gerber, director of patient advocacy and education for the Community Oncology Alliance, discusses the importance of patient education in encouraging clinical trial participation, as well as the importance of trials being patient centered.
Rose Gerber, director of patient advocacy and education for the Community Oncology Alliance, discusses the importance of patient education in encouraging clinical trial participation, as well as the importance of trials being patient centered.
Transcript
How important of a role does education play in encouraging clinical trial participation?
I think the education component is really important because when a patient is sitting in front of their doctor and they’re just having that simple dialogue, it’s building trust. Pretty much the entire population sees an oncologist or any doctor as a very competent individual. So, when they’re sitting there and their doctor is telling them about all the risks and benefits of a trial, I think that starts to put the patient’s mind at ease.
While clinical trials are important for collecting data on a drug, why is it important to make sure that trials are patient centered?
I think patient centricity is something that’s a buzz word right now, but really what it means is we really want to make sure that even though scientists have their goals and the goal of testing a new drug is to determine the outcomes, we need to remember there is a real live person this drug is being tested on and the person is not a robot; this is someone with a heart, feelings, emotions, and fears. Especially when you’re newly diagnosed, that’s when you’re the most vulnerable. So, anytime there’s a group of people planning a research study, whether these are the researchers or the oncologist, you need to really think of the patient because that’s actually who it’s going to impact—a real life human being.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More